REDONDO BEACH, CA--(Marketwired - Oct 31, 2016) -, a leading financial news and information portal offering free real time public company filing alerts, announces an article discussing AXIM Biotechnologies' (OTCQB: AXIM) recently announced closing of a private funding round that will allow the company to continue clinical trials related to the treatment of a variety conditions. AXIM is focused on cannabinoids, and particularly the development of novel and more effective delivery methods for these and other compounds.

AXIM's CanChew® is the world's first patented controlled-release cannabinoid chewing gum and is currently available as an over-the-counter supplement. AXIM has taken things a step further with the development of MedChewRx™, the company's pharmaceutical candidate that combines cannabidiol (CBD) and tetrahydrocannabinol (THC), both naturally extracted and synthetic, in a patented controlled-release chewing gum.

The focus on chewing gum, and the patent behind this unique delivery method, is of particular interest. The company's researchers have proven that the act of chewing -- known as mastication in the medical community -- could also have neurological benefits. According to a growing body of research, the act of chewing could prevent cognitive dysfunction by changing internal carotid arterial blood flow and thereby increasing cerebral circulation/ perfusion. Chewing gum could therefore cause regional increases in neuronal activity that could be cognitively beneficial. Combined with the therapeutic action of the APIs (active pharmaceutical ingredients), MedChew Rx aims to improve the efficacy over existing medications.

AXIM is currently in the early stages of multiple Phase I-II trials to determine the efficacy of MedChew in the treatment of pain and spasticity related to multiple sclerosis as well as other indications, such as IBS, IBD and Crohn's disease. The recently secured funding should allow the company to complete these trials. Multiple sclerosis patients suffering from pain and spasms account for an estimated $4.8 billion market. Showing efficacy here would greatly enhance the value of the company.

AXIM also has a patent-pending drug called AX-1602 which is the world's first CBG (cannabigerol)/CBD-based candidate for treatment of psoriasis and atopic dermatitis currently undergoing clinical trials. These conditions affect over 20 million Americans and many more worldwide, and there is a dearth of effective treatments without harmful side effects.

Click here to read the full article:


Founded in 2004, provides free real time filing alerts to over 600,000 registered members and offers services to help public companies grow their audience of interested investors.


Except for the historical information presented herein, matters discussed in this release contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. Emerging Growth LLC, which owns, is not registered with any financial or securities regulatory authority, and does not provide nor claims to provide investment advice or recommendations to readers of this release. Emerging Growth LLC may from time to time have a position in the securities mentioned herein and may increase or decrease such positions without notice. For making specific investment decisions, readers should seek their own advice. Emerging Growth LLC may be compensated for its services in the form of cash-based compensation or equity securities in the companies it writes about, or a combination of the two. For full disclosure please visit:

Contact Information:
Paul Archie